M J Hosseinzadeh-Attar1, A Golpaie2, M Foroughi2, F Hosseinpanah3, S Zahediasl4, F Azizi5. 1. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, No#44, Hojjatdoost St, Naderi Ave, Keshavarz Bld, Tehran, Iran. hosseinzadeh.md.phd@gmail.com. 2. Department of Nutrition and Biochemistry, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 3. Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Obesity Research Center and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran.
Abstract
AIM: To evaluate the relationship between inflammatory and pro inflammatory markers, with obesity and visceral adiposity in male subjects with or without metabolic syndrome (MS). SUBJECTS AND METHODS: A total of 37 patients with MS and 37 age matched controls were included (mean age 46.35 ± 1.6 years). MS was defined by the criteria of the international diabetes federation 2005. Anthropometric and biochemical profiles, including high-sensitivity C-reactive protein (Hs-CRP), visfatin and interleukin 6 (IL-6), were measured. Data were compared between groups by using t test. Pearson's correlation was used to evaluate the relationship between variables. P values less than 0.05 were considered as statistically significant. RESULTS: In patients with MS, CRP and IL-6 were significantly correlated with body mass index, waist circumference and waist to hip ratio. Visfatin levels were significantly lower in patients with MS compared to controls (log visfatin: 1.74 ± 0.27 vs. 1.86 ± 0.13 ng/ml, MS vs. control group respectively). We cannot find any significant correlation between visfatin, CRP and IL-6. Also there were no correlation between visfatin levels and any anthropometric parameters in patients with MS or control groups. CONCLUSION: Serum visfatin was lower in patients with MS. Therefore it seems that visfatin could not be considered as a pro inflammatory adipocytokine in MS. The positive associations of obesity and visceral adiposity with elevated CRP and IL-6 levels suggest the importance of reducing visceral adiposity to prevent the risk of coronary disease.
AIM: To evaluate the relationship between inflammatory and pro inflammatory markers, with obesity and visceral adiposity in male subjects with or without metabolic syndrome (MS). SUBJECTS AND METHODS: A total of 37 patients with MS and 37 age matched controls were included (mean age 46.35 ± 1.6 years). MS was defined by the criteria of the international diabetes federation 2005. Anthropometric and biochemical profiles, including high-sensitivity C-reactive protein (Hs-CRP), visfatin and interleukin 6 (IL-6), were measured. Data were compared between groups by using t test. Pearson's correlation was used to evaluate the relationship between variables. P values less than 0.05 were considered as statistically significant. RESULTS: In patients with MS, CRP and IL-6 were significantly correlated with body mass index, waist circumference and waist to hip ratio. Visfatin levels were significantly lower in patients with MS compared to controls (log visfatin: 1.74 ± 0.27 vs. 1.86 ± 0.13 ng/ml, MS vs. control group respectively). We cannot find any significant correlation between visfatin, CRP and IL-6. Also there were no correlation between visfatin levels and any anthropometric parameters in patients with MS or control groups. CONCLUSION: Serum visfatin was lower in patients with MS. Therefore it seems that visfatin could not be considered as a pro inflammatory adipocytokine in MS. The positive associations of obesity and visceral adiposity with elevated CRP and IL-6 levels suggest the importance of reducing visceral adiposity to prevent the risk of coronary disease.
Authors: Ji A Seo; Eun Suk Jang; Baek Gil Kim; Ohk Hyun Ryu; Hee Young Kim; Kye Won Lee; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi; Nan Hee Kim Journal: Diabetes Res Clin Pract Date: 2007-09-27 Impact factor: 5.602
Authors: M Miler; N Nikolac; D Segulja; S Kackov Maslac; I Celap; K Altabas; S Sefer; A M Simundic Journal: J Endocrinol Invest Date: 2016-09-06 Impact factor: 4.256
Authors: R Kawamoto; D Ninomiya; Y Kasai; K Senzaki; T Kusunoki; N Ohtsuka; T Kumagi Journal: J Endocrinol Invest Date: 2018-02-19 Impact factor: 4.256
Authors: Zohreh Mousavi; Azita Ganji; Donya Farrokh Tehrani; Ali Bahari; Abbas EsmaeilZadeh; Mehdi Delghandi Journal: Med J Islam Repub Iran Date: 2017-05-28
Authors: Essam Abdel-Sattar; Eman T Mehanna; Sabah H El-Ghaiesh; Hala M F Mohammad; Hanan A Elgendy; Sawsan A Zaitone Journal: Front Pharmacol Date: 2018-08-30 Impact factor: 5.810
Authors: Sergio Sola-Rodríguez; José Antonio Vargas-Hitos; Blanca Gavilán-Carrera; Antonio Rosales-Castillo; Raquel Ríos-Fernández; José Mario Sabio; Alberto Soriano-Maldonado Journal: Front Immunol Date: 2021-10-14 Impact factor: 7.561